Home » Stocks » Evelo Biosciences

Evelo Biosciences, Inc. (EVLO)

Stock Price: $4.20 USD -0.20 (-4.55%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 193.76M
Revenue (ttm) n/a
Net Income (ttm) -88.21M
Shares Out 46.13M
EPS (ttm) -2.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $4.20
Previous Close $4.40
Change ($) -0.20
Change (%) -4.55%
Day's Open 4.36
Day's Range 4.17 - 4.51
Day's Volume 107,064
52-Week Range 3.01 - 9.27

More Stats

Market Cap 193.76M
Enterprise Value 168.62M
Earnings Date (est) Jul 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.13M
Float 16.13M
EPS (basic) -2.74
EPS (diluted) -2.75
FCF / Share -2.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.39M
Short Ratio 22.22
Short % of Float 17.06%
Beta 1.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.19
Revenue n/a
Operating Income -88.81M
Net Income -88.21M
Free Cash Flow -76.09M
Net Cash 25.14M
Net Cash / Share 0.54
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -49.32%
ROE -111.50%
ROIC -305.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(145.95% upside)
Current: 4.20
Target: 10.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-86.36-58.10-27.53-13.03
Net Income-85.47-56.95-28.05-13.33
Shares Outstanding32.0321.873.752.83
Earnings Per Share-2.67-2.78-9.10-5.28
Operating Cash Flow-71.98-47.28-23.27-12.31
Capital Expenditures-3.03-5.29-1.74-1.22
Free Cash Flow-75.01-52.57-25.01-13.54
Cash & Equivalents77.8314838.2515.54
Total Debt19.6312.319.979.93
Net Cash / Debt58.2013628.285.61
Book Value60.20137-54.72-28.34
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Evelo Biosciences, Inc.
Country United States
Employees 98
CEO Balkrishan Gill

Stock Information

Ticker Symbol EVLO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EVLO
IPO Date May 9, 2018


Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.